

1 **Effect of Immunoabsorption on clinical presentation and** 2 **immune alterations in COVID-19-associated ME/CFS**

3 Moritz Anft^{1*}, Lea Wiemers^{1*}, Kamil Rosiewicz^{2*}, Adrian Doevelaar¹, Sarah
4 Skrzypczyk¹, Julia Kurek¹, Sviatlana Kaliszczyk^{1,2}, Maximilian Seidel¹, Ulrik
5 Stervbo^{1,2}, Felix S. Seibert¹, Timm H. Westhoff¹, Nina Babel^{1,2}

6 * These authors contributed equally to the manuscript

7 ¹Center for Translational Medicine and Immune Diagnostics Laboratory, Medical
8 Department I, Marien Hospital Herne, University Hospital of the Ruhr-University
9 Bochum, Hölkeskampring 40, 44625 Herne, Germany

10 ²Berlin Institute of Health, Berlin-Brandenburg Center for Regenerative Therapies,
11 and Institute of Medical Immunology, Charité – Universitätsmedizin Berlin, Corporate
12 Member of Freie Universität Berlin, Humboldt-Universität zu Berlin Augustenburger
13 Platz 1, 13353 Berlin, Germany

14
15 Corresponding author:

16 Prof. Nina Babel

17
18 Center for Translational Medicine, Medical Department I, Marien Hospital Herne,
19 University Hospital of the Ruhr-University Bochum, Hölkeskampring 40, 44625
20 Herne, Germany and Berlin Institute of Health, Charité – Universitätsmedizin Berlin,
21 Augustenburger Platz 1, 13353 Berlin, Germany

22

23 Email: nina.babel@rub.de; nina.babel@charite.de

24 Keywords: SARS-CoV-2, Post-Covid, Immunoabsorption

Abstract

Autoreactive antibodies (AAB) are currently being investigated as causative or aggravating factors during post-COVID. In this study we analyze the effect of immunoadsorption therapy on symptom improvement and the relationship with immunological parameters in post-COVID patients exhibiting symptoms of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). This observational study includes 12 post-COVID patients exhibiting a predominance of ME/CFS symptoms alongside increased concentrations of autonomic nervous system receptors (ANSR) autoantibodies and neurological impairments. We found that following immunoadsorption therapy, the ANSR autoantibodies were nearly eliminated from the patients' blood. The removal of IgG antibodies was accompanied by a decrease of pro-inflammatory cytokines including IL4, IL2, IL1 β , TNF and IL17A serum levels, and a significant reduction of soluble spike protein. Notably, a strong positive correlation between pro-inflammatory cytokines and ANSR-AABs β 1, β 2, M3, and M4 was observed in spike protein-positive patients, whereas no such correlation was evident in spike protein-negative patients. 30 days post-immunoadsorption therapy, patients exhibited notable improvement in neuropsychological function and a substantial amelioration of hand grip strength was observed. However, neither self-reported symptoms nor scores on ME/CSF questionnaires showed a significant improvement and a rebound of the removed proteins occurring within a month.

Introduction

While the SARS-CoV-2 pandemic has decreased in intensity over time due to vaccinations and the emergence of less pathogenic virus variants, some patients manifest an array of different symptoms several months after the initial COVID-19 infection. These sequelae are collectively termed Long- or Post-COVID. The detailed research into Post-COVID reveals it to be a heterogeneous clinical picture with over 200 documented different symptoms arising from various causes.¹ These symptoms are often nonspecific and can impact multiple organs. Alongside cardiovascular symptoms like palpitations or chest pain,²⁻⁴ patients often report respiratory issues such as breathlessness.⁵ Importantly, neurological and cognitive symptoms including cognitive decline, memory impairment, and fatigue are prevalent among patients experiencing severe Post-COVID effects, leading to significant limitations and even complete immobilization.⁶⁻⁸ These symptoms associate with autoantibodies against G protein-coupled receptors (GPCRs) of autonomic nervous system.⁹

Based on current research findings, four main causes can be broadly distinguished as responsible for the array of symptoms.¹⁰

1.) Persistent SARS-CoV-2 virus reservoirs in tissues: Numerous studies have identified SARS-CoV-2 RNA in various tissues,^{11,12} as lung, lymph nodes, and plasma.¹³⁻¹⁵ Additionally, in post-COVID patients, soluble spike protein has been detected in plasma even a year after initial SARS-CoV-2 infection.¹⁶ It is hypothesized that active, persistent reservoirs of SARS-CoV-2 virus exist in the tissues of a significant portion of post-COVID patients, contributing to the development of subsequent post-COVID symptoms.¹⁷

2.) Autoantibody (AAB) formation:¹⁸ Infection with SARS-CoV-2 can trigger the formation of autoantibodies targeting components of the immune system, the cardiovascular system, the thyroid gland, as well as rheumatoid-specific autoantibodies and antibodies against G-protein-coupled receptors (GPCR).¹⁹ Studies show a correlation in the concentration of GPCR AAB with the severity of neurological symptoms.²⁰

3.) Reactivation of latent viruses: Particularly, the reactivation of various herpes viruses like EBV and HHV-6 has been observed in post-COVID patients, correlating with mitochondrial fragmentation and decreased energy metabolism.²¹

4.) Tissue damage from inflammatory processes: Post-COVID patients exhibit elevated levels of pro-inflammatory cytokines such as IL-1 β , IL-6, TNF, or IP10, which can lead to neurological and kidney damage or diabetes mellitus.²²⁻²⁴ Additionally, microvascular blood clots with endothelial dysfunction have been detected in a substantial number of patients, associated with symptoms like fatigue, thrombosis, and microclots.^{25,26}

The presence of autoantibodies in the majority of post-COVID patients makes immunoadsorption (IA) an attractive therapeutic strategy. There are a variety of different adsorbents, allowing the non-selective removal of all subclasses of immunoglobulins such as IgG or more selective removal of disease-specific molecules such as lipoproteins and CRP. In the context of post-COVID syndrome, IgG immunoadsorption is particularly relevant since it can specifically eliminate autoantibodies. However, preliminary reports on the efficacy of IA in post-COVID are contradictory, rising the need to establish a broader scientific basis.²⁷⁻²⁹

This study aims to explore the impact of IA on neuropsychological impairments in relation to humoral and cellular immune response in post-COVID patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). The objective is to explore the impact of IA-therapy on diverse markers associated with post-COVID conditions, including autoantibodies directed against autonomic nervous system receptors, soluble spike protein levels, pro-inflammatory cytokines, and the composition of the cellular immune system, both pre- and thirty days after therapy.

Results

In this study, 12 post-COVID patients with ME/CSF symptoms and high levels of GCPR AAB against autonomic nervous system receptors (ANSR) were evaluated for clinical symptoms, physical and mental health status and immunological characteristics before and after immunoadsorption (IA) therapy. The patients were two-thirds female and with a median age of 50 and a median BMI of 25.25. Among them, 4 out of 12 had ME/CSF developed after SARS-CoV-2 infection, while the remaining 8 described their ME/CSF originally induced by other factors, later aggravated by a subsequent SARS-CoV-2 infection. Table 1 demonstrates patient characteristics and comorbidities. Inclusion criterium was elevated levels of at least 3 of the 4 ANSR proteins β 1-adrenergic receptor (>15 U/mL), β 2-adrenergic receptor (>8 U/mL), M3-mACh receptor (>6 U/mL), and M4-mACh receptor (>10.7 U/mL). Over a span of 10 days, patients underwent 5 sessions of IA-therapy, with comprehensive screening conducted prior to the first session, after the last session and 30 days after the last session. Health status and symptoms were assessed through detailed anamnesis, while physical examinations encompassed quantification of handgrip strength. Neurological and mental well-being were quantified via the SF-36 questionnaire and various fatigue scores, while dysfunction of the autonomic nervous system was gauged using the COMPASS-31 score. Blood was immunologically analyzed during both assessments and following the last IA session (Figure 1A).

IA-therapy leads to a strong decrease in ANSR-AABs and to an improvement in multiple physical and neuropsychological factors

Quantifying the ANSR autoantibodies in the patients' serum immediately after the final therapy session revealed that the levels of autoantibodies was significantly reduced below their respective threshold values through IA. 30 days later, however, the concentration of autoantibodies had returned to a slightly, but not significantly, lower level compared to the time before therapy (Figure 1B). 30 days after IA-therapy, the patients had median autoantibody levels of 93.9% (β 1), 74.8% (β 2), 82.4% (M3), and 88.8% (M4) compared of the baseline levels before IA (Supplemental Table S1). In addition, several physical and neuropsychological were observed following the IA. Patients exhibited significantly increased hand strength

post-therapy (Figure 1C). Moreover, the overall score of the CERAD test battery was significantly higher at the one-month follow-up measurement, primarily attributed to enhancements in word learning, fluent speaking, and the Trail Making Test B (Figure 1D).

IA-therapy does not lead to self-perceived changes

In addition to these objective measurements, several questionnaires and anamnesis were used to assess patients' self-perception of whether and how their symptoms and physical and mental health changed after the therapy (Table 2). The surveys revealed no significant differences in the perception of physical and mental health following the IA-therapy. Neither in the SF-36 questionnaire regarding health-related quality of life nor in the Chandler Fatigue Score, Bell Score, or the Canadian criteria for ME/CFS showed a significant improvement or deterioration due to the therapy (Table 2 – upper section). Additionally, the self-reported symptoms of the patients did not differ 30 days after the last IA compared to before the therapy (Table 2 – lower section).

Temporary reduction in pro-inflammatory cytokines

The concentration of pro-inflammatory cytokines in the serum of patients was examined before and after the IA. Especially IL-4, IL-2, IL-1 β , TNF and IL-17A were significantly reduced immediately after the IA compared to the pre-therapy level. Similar to the concentration ANSR AABs, the concentration of all these cytokines rose back to a similar level as before the IA-therapy in the follow-up analysis 30 days later. Interestingly, the concentration of TGF β 1 increased significantly directly after IA and dropped back to the pre-IA level in the follow-up analysis, and the concentration of IL-8 was significantly reduced after IA-therapy (Figure 2). The concentration of other cytokines such as IP-10, MCP-1, IL-6 and IL-10 were not changed by the therapy (Supplemental Figure S1). In addition, 5 of the 12 patients had an acute EBV infection with an elevated EBV load during the whole study, and the viral load did not change during and after IA-therapy (Supplementary Figure S2).

Cellular immunity is unaffected by IA

To explore if the perturbations in pro-inflammatory cytokines during IA-therapy had any effect on the composition of T cell populations, the major T cell populations

before and 30 days after IA-therapy were examined. While there were no differences in the percentage of total CD4⁺ and CD8⁺ T cells, patients demonstrated significantly more naive and significantly fewer memory CD4⁺ T cells and additionally significantly fewer CXCR5 expressing follicular helper cells in the follow-up examination compared to the data before the start of IA-therapy (Figure 3A+3C).

T cells may become exhausted in a prolonged pro-inflammatory.³⁰ We therefore explored whether this is the case in post-COVID before and after IA-therapy. The frequency of PD-1 expression on CD4⁺ and CD8⁺ T-cells prior to the therapy was within previously observed ranges (Figure 3A+C)³¹. Except for a significant decrease in Tim-3 expressing CD4 T cells, there were no differences in the expression of exhaustion markers PD-1, Tim-3, CTLA-4, or Lag-3 directly or 30 days after IA (Figure 3 A+C and Supplemental Figure S3).

To investigate if the autoimmunity towards autonomic nervous system receptors extended to the T cells, PBMC were stimulated with pooled lysates of β 1/ β 2-adrenoceptors and muscarinic M3/M4 receptors, respectively (Figure 3B+D). Simultaneously, the potential impact on cellular immunity to SARS-CoV-2 was examined by additionally stimulating of PBMC with a pool of SARS-CoV-2 spike protein overlapping peptides (Figure 3B+D). ANSR specific T cells were quantified by assessing the expression of CD137 on CD8⁺ T cells and CD137 and CD154 on CD4⁺ T cells. Following IA-therapy, there were no discernible differences in the percentages of CD4 and CD8 T cells specific to β 1/ β 2-adrenoceptors or muscarinic M3/M4 receptors compared to the respective frequencies before IA-therapy. Moreover, although a slight yet significant decrease was noted specifically in the proportion of naive CD4 T cells targeting M3+M4 after IA, no significant differences were observed in the proportions of naive, memory, and exhausted ANSR-specific T cells post-IA (Figure 3B+D and supplemental Figure S4).

IA-Therapy leads to a temporary reduction of SARS-CoV-2 spike protein

Several studies have shown that a subset of post-COVID patients have detectable levels of soluble spike protein in their blood.^{16,17} The next step was to investigate the development of spike protein levels in the patients in this study before the IA-therapy, immediately after the last IA and at follow-up. Before the first IA, soluble spike protein was detected in 6 out of 12 patients, with a median concentration of 207.7 pg/mL.

Following the IA-therapy, the concentration of soluble spike protein significantly dropped to 22.8 pg/mL, but rebounded to a median of 207.5 pg/mL by the 30-day follow-up examination (Figure 4A). Except for one patient, the IA-therapy also significantly reduced the concentration of SARS-CoV-2 spike protein specific antibodies, but these levels also returned to their initial values within the 30 days following IA (Figure 4B). However, we found no differences in the frequency of spike protein specific CD4⁺ or CD8⁺ T cells after the IA-therapy (Figure 4C).

Correlation between neurological symptoms, virological and immunological status

As stated above, the ratio of patients identified with soluble spike protein at study start was 50:50, whereas 100% of patients showed detectable SARS-CoV-2 specific antibodies. This interesting result led to the question, if there are possible differences between these two groups based on the detected soluble spike protein (groups named as "spike-" and "spike+"). First, spike+ patients were characterized by significantly strong positive correlations between spike+ protein and SARS-CoV-2 specific antibodies, ANSR autoantibodies (β 1, β 2 and M3) and pro-inflammatory cytokines IP-10 and IL-6 (Figure 4D). SARS-CoV-2 specific antibodies showed not only nearly the same significant correlation with ANSR autoantibodies (β 2, M3 and M4) but also with pro-inflammatory cytokines IL-2, IL-1 β , IL-6 and IL-12p70 and a significant negative correlation to the anti-inflammatory cytokine TGF β 1. In general, all ANSR autoantibodies showed very strong correlations to all cytokines except for MCP-1, INF γ and TGF β 1. This result was in strong contrast to spike- patients. Here, SARS-CoV-2 spike protein specific antibody levels correlated only positively with blood levels of IL-1 β and INF γ . Interestingly, ANSR autoantibody levels (β 2, M3, M4) showed a significant negative correlation to TGF β 1 blood levels. Only the positive correlation between ANSR autoantibody levels and SARS-CoV-2 specific antibody levels had spike- and spike+ patients in common (Figure 4D).

Next, the detected levels of soluble spike protein, SARS-CoV-2 specific antibodies and ANSR autoantibodies were correlated with the monitored clinical ME/CSF data. Again, spike+ patients showed a slightly different correlation profile than spike- patients. Soluble spike protein levels correlated significantly positive with MBSQ total score, while significantly negative with CERAD-Plus score and CERAD-Plus (word list learning) (Figure 4E).

227 This study shows that TheraSorb IA-therapy has the potential to improve the
228 neuropsychological state of ME/CFS, but has no positive impact on self-perceived
229 symptoms and mental health. In addition to ANSR-AABs, it effectively removes the
230 soluble spike protein, decreases pro-inflammatory cytokines and increase
231 inflammatory cytokine TGF β . However, these improvements are highly transient, with
232 a resurgence of the eliminated proteins happening within a month. Further
233 therapeutic steps are needed to be implemented to provide a long-term
234 immunological and symptomatic improvements

Discussion

Although the SARS-CoV-2 pandemic is over, humankind is still struggling with its consequences years later. The occurrence of post-COVID after SARS-CoV-2 infections poses major challenges for both patients and healthcare providers. The multiple symptoms and underlying causes make diagnosis and treatment complex and difficult. ANSR autoantibodies are associated with disease severity in ME/CSF and their removal is associated with moderate improvement in symptoms in a previous study.²⁸ The present study shows that the health status of post-COVID patients with ME/CFS symptoms and high ANSR autoantibody levels objectively improved after IA-therapy. However, the affected patients did not perceive any improvement as reflected in the self-reported symptoms.

In the present study, all patients had high titers of ANSR autoantibodies against $\beta 1/\beta 2$ -adrenoceptor and muscarinic M3/M4 receptor. These ANSR and other GPCR autoantibodies were earlier associated with the occurrence and worsening of multiple diseases like cardiovascular or rheumatic diseases,^{32–34} and several studies have shown a correlation between the presence of these ANSR autoantibodies and the severity of post-COVID.^{9,35–37} In the context of ME/CSF and post-COVID, it has been shown that ANSR autoantibodies may be associated with Postural Orthostatic Tachycardia Syndrome (POTS).^{38,39} It is suggested that these ANSR autoantibodies can disrupt autonomic nervous system function by interfering with signaling pathways through binding to ANSRs, leading to symptoms such as excessive increase in heart rate upon standing, dizziness, and fatigue.⁴⁰ The patients in this study also reported these neurological and hemodynamic symptoms and were diagnosed with fatigue. Self-assessments using the SF-36 questionnaire revealed substantial deficits in both physical and mental health. Additionally, the Bell and Chalder Fatigue Scores were low, consistent with findings from studies on post-COVID patients with ME/CFS symptoms.⁴¹ IA-therapy could effectively remove ANSR autoantibodies in patients with ME/CSF and provided a moderate improvement in symptoms in the period shortly after therapy.^{28,42} In line with this, an overall score increase in the CERAD+ neuropsychological test as well as an increase in hand strength after removal of the ANSR autoantibodies in this study was observed.

As also reported in other studies,^{28,42} the levels of autoantibodies returned to their original levels one month after therapy, which could be the reason that in contrast to the improvement of objective symptoms, there was no demonstrated improvement in the quantified fatigue scores and self-reported symptoms by the patients in the follow-up. While neurological symptoms such as tiredness, cephalgia and brain fog were present in almost all patients before therapy, they did not improve by IA-therapy and the removal of ANSR autoantibodies. Accordingly, physical and mental health were at the same low level after IA-therapy as before treatment, suggesting that short-term removal of these AABs from the blood by IA-therapy cannot effectively treat post-COVID symptoms. In contrast, removal of ANSR autoantibodies in a post-COVID patient using the DNA aptamer BC 007 resulted in a significant and four-week lasting improvement in symptoms such as fatigue symptoms, taste and capillary microcirculation⁴³. It is possible that a long-lasting DNA aptamer neutralizes ANSR autoantibodies over an extended period, rather than only targeting the antibodies present during the therapy, as is the case with IA-therapy. Moreover, IA-therapy can only filter AABs out of the blood, whereas DNA aptamers can also act at the tissue level.⁴⁴

Interestingly, changes in pro-inflammatory cytokine levels were detected after the IA-therapy. While some cytokines, such as IL-2, IL-4, and IL-17A, were reduced immediately after the final IA-therapy TGFβ1 levels were elevated. Other cytokines, like IP-10 and MCP-1, were not significantly affected by the therapy. The reason for the changes in cytokine levels after IA remains speculative. The different impact of IA on certain cytokines demonstrates that this is not a pure mechanical cytokine elimination. There might be a general reduction in inflammation after IA, as autoantibodies drive inflammation via the activation of the complement system or direct antibody-dependent activation of immune cells.^{45–47} Furthermore, patients with infectious or autoimmune diseases have autoantibodies against some cytokines that bind to the IA column, which could also remove bound cytokines.^{48–50}

While the presence of ANSR autoantibodies indicate a defective immunotolerance after a viral infection,^{51,52} the existence of soluble spike protein in post-COVID patients may indicate an active, persistent infection with SARS-CoV-2 viruses as it is currently discussed. Persistent viral reservoirs are known from other RNA viruses such as Ebola or Measles and are found in various tissues.^{53,54} The presence of

soluble SARS-CoV-2 spike protein in 6 of the 12 patients suggests that half of the post-COVID patients in this study contain active virus reservoirs in their tissues that release spike protein into the bloodstream. Interestingly, spike protein was also largely removed from the patients' blood with IA-therapy, even though they were not expected to bind to the Ig-column. However, since high titers of SARS-CoV-2 spike protein specific antibodies were detected in all patients, it is likely that these antibodies bound to soluble spike protein, leading to their removal along with the antibodies during IA-therapy. Notable, there was no improvement in self-reported symptoms after IA-therapy associated with the removal of spike proteins in patients with soluble spike protein, which is consistent with the observation that spike positive patients do not show significant correlations between spike level and ME/CSF test scores. Whether and how soluble spike protein itself has a direct pathogenic effect or if the active virus reservoirs lead to the manifestation and exacerbation of post-COVID symptoms is not yet clear. It is discussed that soluble spike protein directly leads to the formation of fibrin and amolytic microclots, which should be prevented by removing spike protein from the body.⁵⁵ Additionally, it has been shown in mice that spike protein injected in the brain can lead to neuropsychological impairments that are similar to post-COVID symptoms,⁵⁶ although it remains highly unclear, whether the spike protein crosses the blood-brain barrier in humans and can be responsible for similar mechanisms. However, since IA-therapy does not address the source of the soluble spike protein, the ongoing production of spike protein due to persistent infection may prevent a beneficial effect. This would be supported by the fact that the level of spike protein almost returned to its original level shortly after the last IA session. It is also noteworthy that a strong correlation between the amount of all ANSR autoantibodies tested and most pro-inflammatory cytokines was only seen in the spike positive patients, which is only the case for $\beta 1$ AAB in the spike negative patients. It could be assumed that a persistent infection leads to increased inflammation and generation of auto-reactive antibodies. Moreover, previous studies demonstrated a clear association between inflammation and autoimmunity.⁵⁷

Also some changes at the cellular level were observed after IA-therapy. There was a significant reduction in CD4⁺ central memory and follicular helper T cells, accompanied by an increase in the frequency of naive T cells. A direct interaction and removal of the cells by the Ig-binding apheresis column can be excluded due to the high specificity of the column.⁵⁸ However, the IA procedure might lead to a

temporary redistribution of T cell subsets within the body. The stress associated with the treatment could trigger a short-term migration of T cells from the bloodstream to various tissues, causing an apparent reduction of these cells in the peripheral blood. Additionally, the observed changes in the cytokine profile, which is fundamental for T cell homeostasis, could impact the maintenance of these T cell populations and result in alterations in the distribution of sub-populations.⁵⁹ One difficulty with persistent and chronic infections is that ongoing activation induced by constant antigen presence can lead to exhaustion and changes in the differentiation of T cells.^{60,61} Consequently, it was shown that T cells from post-COVID patients express higher levels of exhaustion markers PD-1, CTLA-4 and Tim-3.^{62,63} Although this study did not compare the levels of exhaustion markers or the T cell frequencies between post-COVID patients and convalescent controls, any differences in the frequency of ANSR lysate-specific or spike protein-specific T cells and their PD-1, CTLA-4 and Tim-3 expressing T cell subsets before and one month after IA-therapy have been observed. These data suggest that even though these antigens were almost completely removed immediately after therapy, IA-therapy has a short effect on these molecules and obviously no modulating effect on T cells.

The fact that there was no improvement in the patients' perception of their symptoms may also be related to the IA procedure itself. IA-therapy is an invasive procedure that poses a challenge for all patients due to the long duration and use of a Shaldon catheters. Especially for patients in a poor general condition, such as post-COVID patients, this can further increase the level of suffering. In these cases, subjectively reported symptoms may not align with objective measurements

This study has some limitations. This is an observational study, and a randomized control trial including a placebo group is needed to verify the beneficial effect of IA-therapy. Furthermore, the small sample size of 12 patients reduces the statistical power, potentially masking significant changes. Fortunately, much of the laboratory data is consistent enough among patients to allow reasonably firm conclusions. However, the study does not prove a causal relation between ANSR autoantibodies and ME/CFS symptoms, since IA removes other immunoglobulins as well. Another limitation is a potential practicing effect in the neuropsychological tests. However, it has been shown that these can be eliminated or limited by the selection of tests⁶⁴. The follow up at day 30 after IA is relatively short, and it will be necessary to see if

366 the observed improvements are persistent and even lead to a self-assessed
367 improvement.

368 In summary, this study demonstrates that IA-therapy in patients with post-COVID
369 disease and ME/CSF symptoms leads to a significant reduction in autoantibodies,
370 soluble spike protein, and inflammatory cytokines. This is accompanied by moderate
371 improvements in neuropsychological parameters, though it does not influence the
372 patients' subjective perception of their symptoms. These data lay the foundation for
373 further research to determine the extent of these observed benefits for patients and
374 whether this treatment should be considered standard for post-COVID care in the
375 future.

Methods

Study population and design

This observational study involved 12 post-COVID patients exhibiting a predominance of ME/CFS symptoms alongside the presence of ANSR autoantibodies ($\beta 1 > 15$ U/mL; $\beta 2 > 8$ U/mL; M3 > 6 U/mL; M4 > 10.7 U/mL) and neurological impairments. Age over 18 years, ME/CSF syndrome, the presence of 3 of the 4 ANSR AABs and written consent were defined as inclusion criteria. Patients underwent immunoabsorption therapy and blood samples were collected from patients before the initial session, immediately post-treatment, and again after an additional 30 days (Figure 1). The study was approved by the ethical committee of Ruhr university Bochum (Reg.-Nr. 23-7752) and all participants provided a written informed consents.

Immunoabsorption Therapy

Patients underwent a course of TheraSorb - Ig omni 5 adsorber (Miltenyi, Germany) immunoabsorption therapy comprising 5 sessions over a span of 10 days aimed at eliminating IgG antibodies. The therapy was carried out at Marien Hospital Herne in Medical Clinic 1 for Internal Medicine under the supervision of a professional dialysis unit.

Preparation of PBMCs

Peripheral blood was collected in S-Monovette K3 EDTA blood collection tubes (Sarstedt, Germany). Collected blood was pre-diluted in PBS/BSA (Gibco, USA) at a 1:1 ratio and underlaid with 15 mL Ficoll-Paque Plus (GE Healthcare, USA). Tubes were centrifuged at 800 g for 20 minutes at room temperature. Isolated PBMC were washed twice with PBS/BSA and stored at -80°C until use as previously described⁶⁵.

Antigen stimulation of T cells

Isolated PBMC were stimulated with $1\mu\text{g/ml}$ Sars-CoV-2 OPPs (Miltenyi, Germany), $1\mu\text{g/ml}$ $\beta 1+\beta 2$ or $1\mu\text{g/ml}$ M3+M4 purified cell lysates (Biotrend, Germany). 2.5×10^6 PBMCs were plated for each condition in 96-UWell Plates in RPMI media (Life Technologies), supplemented with 1% Penicillin-Streptomycin-Glutamine (Sigma Aldrich, USA), and 10% FCS (PAN-Biotech, USA) and were stimulated or left untreated as a control for 16 hours. As a positive control, cells were stimulated with SEB ($1\mu\text{g/ml}$, Sigma Aldrich, USA) or left untreated as a negative control. After 2

hours, Brefeldin A (1µg/ml, Sigma Aldrich, USA) was added. As previously applied by our groups and others, antigen-specific responses were considered positive after the non-specific background was subtracted, and more than 0.001% or at least 15 positive cells were detectable. Negative values were set to zero.

Measurement of autoantibodies to GPCR

Serum was collected in a S-Monovette Serum collection tube (Sarstedt, Germany) and processed per manufacturer's instructions. Purified serum was stored at -20 °C until use. ELISA systems for detection of autoantibodies against β -1 Adrenergic Receptor (β 1), β -2 Adrenergic Receptor (β 2), Muscarinergic Choline Receptor 3 (M3), and Muscarinergic Choline Receptor 4 (M4) were all obtained from CellTrend, Germany. Autoantibodies in serum were determined per manufacturer's instructions and normalized using the provided standard. The following cut-offs were used to define presence of autoantibodies: β 1: >15 U/ml; β 2: >8 U/ml; M3: >6 U/ml; M4: >10.7 U/ml.

QPCR measurement of EBV virus titer

Peripheral blood samples were monitored for EBV by qPCR. DNA was isolated from whole blood samples using AltoStar Purification Kit 1.5 (Altostar, Germany) and qPCR was performed using AltoStar EBV PCR Kit 1.5 following the manufacturer's instructions. Both Kits were performed on an AltoStar AM16 pipetting robot and qPCR was measured on an BioRad C1000 Thermal Cycler. The detection level was determined as the lowest viral load measured within the range of linearity (250 copies/ml).

Cytokine analysis

Purified serum was stored at -20 °C until use. The level of the cytokines IL-4, IL-2, IP-10 (CXCL10), IL-1 β , TNF- α , MCP-1 (CCL2), IL-17A, IL-6, IL-10, IFN- γ , IL-12p70, IL-8 (CXCL8), and TGF- β 1 (free active) was assessed using the LEGENDplex Human Essential Immune Response Panel (BioLegend, San Diego, USA) per manufacturers instruction and acquired on a CytoFLEX (Beckman Coulter, Germany) flow cytometer. Briefly, serum was incubated with beads coated with antibodies for one of the analyzed cytokines together with a secondary antibody and phycoerythrin-conjugated (PE) detection antibody. Each cytokine is detectable by the bead size and level of allophycocyanin (APC) within the bead, and the intensity of PE is relative to

the levels of the cytokine in the sample. The measured fluorescence intensities were normalized using the provided cytokine standard.

ME/CFS symptoms and neuropsychological evaluation

Long-COVID symptoms were quantified using a 19 items questionnaire based on the ISARIC COVID-19 follow-up study protocol. To quantify the severity of mental and physical fatigue, all patients completed the Chalder fatigue scale, Munich Berlin Symptom Questionnaire (MBSQ) and Epworth Sleepiness Scale (ESS). Physical function and impairment were assessed by the Bell disability scale and the Short Form Health Survey-36 (SF-36). Additionally, hand grip strength was measured as an objective parameter for physical impairment using a hydraulic hand dynamometer (Saehan, Germany). Furthermore, dysautonomic symptoms were evaluated using the COMPASS-31 score. All neuropsychological assessments were conducted using the German version of the “Consortium to Establish a Registry for Alzheimer’s Disease Neuropsychological Assessment Battery” (CERAD). The standard assessment, which includes evaluation of verbal fluency (animal naming), a modified version of the Boston Naming Test, global cognition (Mini-Mental State examination), verbal memory (word list learning, delayed recall), as well as constructional practice and delayed recall, was widened out by additional items on processing speed (Trail Making Test A) and executive functioning (Trail Making Test B, letter fluency: S-words).

Spike Protein Elisa

Serum was collected in a S-Monovette Serum collection tube (Sarstedt, Germany) and stored at -20 °C until use. The concentration of spike protein was assessed using the Human SARS-CoV.2 RBD Elisa Kit (Invitrogen, Thermo Fisher, USA). The Elisa was performed according to the manufacturers technical manual and no alterations were implemented. The optical density of the plates was determined using a Asys UVM 340.

Antibodies

Antigen specific T cells (all antibodies are from BioLegend (USA) unless otherwise noted): Surface staining: CCR7 (CD197)-PerCP-Cy5.5; clone: G043H7, CD4-A700; clone: OKT4, LD eFluor780 (eBioscience, USA), CD8-V500; clone: RPA-T8 (BD Biosciences), CD45RA-BV605; clone: HI100. Intracellular staining: CD137 (4-1BB)-PE-Cy7; clone: 4B4-1, CD154 (CD40L)-A647; clone: 24-31, TNFa-eFluor450; clone: MAb11 (eBioscience, USA), CD3-BV785; clone: OKT3, PD-1-PE; clone: A17188A,

Tim-3-VioBright-Fitc; clone: REA635 (Miltenyi, Germany), CTLA-4-BV421; clone: BNI3, Lag-3-BV650; clone: 11C3C65. Fixable Viability Dye eFluor 780 (eBioscience, USA) was used for live/dead discrimination.

Flow Cytometry

Stimulated PBMC were extracellular stained with optimal concentrations of antibodies for 10 minutes at room temperature in the dark. Cells were washed twice with PBS/BSA before preparation for intracellular staining using the Intracellular Fixation & Permeabilization Buffer Set (Thermo Fisher Scientific) as per manufacturer's instructions. Fixed and permeabilized cells were stained for 30 minutes at room temperature in the dark with an optimal dilution of antibodies against the intracellular antigen.

All samples were immediately acquired on a CytoFlex flow cytometer (Beckman Coulter). Quality control was performed daily using the recommended CytoFlex Daily QC Fluorospheres (Beckman Coulter). No modification to the compensation matrices was required throughout the study. Flow cytometry data were analyzed using FlowJo version 10.6.2 (BD Biosciences); gating strategies are presented in Supplemental Figures S5+S6.

Statistical analysis

Statistical analysis was performed using R, version 4.2.1. Categorical variables are summarized as numbers and frequencies; quantitative variables are reported as mean \pm SD. No data transformation was used. Violin plots depict the median and the first and third quartiles. The whiskers correspond to 1.5 times the interquartile range. All applied statistical tests are paired and two-sided. Dotted lines between violins indicate the individual patients. Differences in quantitative variables between all three groups are analyzed using non-parametric Wilcoxon test. P values below 0.050 were considered significant. P values were not corrected for multiple testing, as this study was of exploratory nature^{66,67}. The normalization standard for the ELISA results was calculated using a four parameter logistic regression. Parameter correlation was assessed using Spearman's rank correlation coefficient.

502 Author contributions

503 Conceptualization: T.W. and N.B.; Data curation: M.A., L.W., K.R. and U.S.; Formal
504 analysis: M.A., L.W., K.R. and U.S.; Funding acquisition: N.B.; Investigation: M.A.,
505 L.W., K.R., S.S., J.K., S.K., U.S. and N.B.; Methodology: M.A., U.S. and N.B.;
506 Resources: A.D., F.S. and T.W.; Visualization: M.A. and K.R.; Writing – original draft:
507 M.A., L.W., K.R., U.S. and N.B.; Writing - review & editing: M.A., L.W., K.R., U.S. and
508 N.B.;

509 Acknowledgments

510 We want to express our deepest gratitude to the patients who donated their blood
511 samples and clinical data for this project. We thank Miltenyi Biotec who supported our
512 study by providing materials and equipment (TheraSorb columns) for
513 Immunoabsorption. This work was further supported by DFG grants NFDI4
514 (501875662)

515 Conflict of interest

516 The study was initiated by the investigators themselves. They independently created
517 the study without any external guidance or involvement from entities like Miltenyi
518 Biotec or any other undisclosed parties, pertaining to its design, analysis, data
519 interpretation or manuscript approval. The authors themselves did not receive any
520 payment related to this study and have stated that they have no conflicting interests.

References

1. Davis, H.E., McCorkell, L., Vogel, J.M., and Topol, E.J. (2023). Long COVID: major findings, mechanisms and recommendations. *Nat. Rev. Microbiol.* 21, 133–146. <https://doi.org/10.1038/s41579-022-00846-2>.
2. Carfi, A., Bernabei, R., Landi, F., and for the Gemelli Against COVID-19 Post-Acute Care Study Group (2020). Persistent Symptoms in Patients After Acute COVID-19. *JAMA* 324, 603. <https://doi.org/10.1001/jama.2020.12603>.
3. Ramadan, M.S., Bertolino, L., Zampino, R., Durante-Mangoni, E., Durante-Mangoni, E., Iossa, D., Bertolino, L., Ursi, M.P., D'Amico, F., Karruli, A., et al. (2021). Cardiac sequelae after coronavirus disease 2019 recovery: a systematic review. *Clin. Microbiol. Infect.* 27, 1250–1261. <https://doi.org/10.1016/j.cmi.2021.06.015>.
4. Carvalho-Schneider, C., Laurent, E., Lemaigen, A., Beauvils, E., Bourbao-Tournois, C., Laribi, S., Flament, T., Ferreira-Maldent, N., Bruyère, F., Stefic, K., et al. (2021). Follow-up of adults with noncritical COVID-19 two months after symptom onset. *Clin. Microbiol. Infect.* 27, 258–263. <https://doi.org/10.1016/j.cmi.2020.09.052>.
5. Daines, L., Zheng, B., Elneima, O., Harrison, E., Lone, N.I., Hurst, J.R., Brown, J.S., Sapey, E., Chalmers, J.D., Quint, J.K., et al. (2023). Characteristics and risk factors for post-COVID-19 breathlessness after hospitalisation for COVID-19. *ERJ Open Res.* 9, 00274–02022. <https://doi.org/10.1183/23120541.00274-2022>.
6. Jaywant, A., Gunning, F.M., Oberlin, L.E., Santillana, M., Ognyanova, K., Druckman, J.N., Baum, M.A., Lazer, D., and Perlis, R.H. (2024). Cognitive Symptoms of Post-COVID-19 Condition and Daily Functioning. *JAMA Netw. Open* 7, e2356098. <https://doi.org/10.1001/jamanetworkopen.2023.56098>.
7. Li, Z., Zhang, Z., Zhang, Z., Wang, Z., and Li, H. (2023). Cognitive impairment after long COVID-19: current evidence and perspectives. *Front. Neurol.* 14. <https://doi.org/10.3389/fneur.2023.1239182>.
8. Quan, M., Wang, X., Gong, M., Wang, Q., Li, Y., and Jia, J. (2023). Post-COVID cognitive dysfunction: current status and research recommendations for high risk population. *Lancet Reg. Health – West. Pac.* 38. <https://doi.org/10.1016/j.lanwpc.2023.100836>.
9. Sotzny, F., Filgueiras, I.S., Kedor, C., Freitag, H., Wittke, K., Bauer, S., Sepúlveda, N., Mathias da Fonseca, D.L., Baiocchi, G.C., Marques, A.H.C., et al. (2022). Dysregulated autoantibodies targeting vaso- and immunoregulatory receptors in Post COVID Syndrome correlate with symptom severity. *Front. Immunol.* 13, 981532. <https://doi.org/10.3389/fimmu.2022.981532>.
10. Iwasaki, A., and Putrino, D. (2023). Why we need a deeper understanding of the pathophysiology of long COVID. *Lancet Infect. Dis.* 23, 393–395. [https://doi.org/10.1016/S1473-3099\(23\)00053-1](https://doi.org/10.1016/S1473-3099(23)00053-1).
11. Machkovech, H.M., Hahn, A.M., Wang, J.G., Grubaugh, N.D., Halfmann, P.J., Johnson, M.C., Lemieux, J.E., O'Connor, D.H., Piantadosi, A., Wei, W., et al. (2024). Persistent SARS-CoV-2 infection: significance and implications. *Lancet Infect. Dis.* 24, e453–e462. [https://doi.org/10.1016/S1473-3099\(23\)00815-0](https://doi.org/10.1016/S1473-3099(23)00815-0).
12. Ghafari, M., Hall, M., Golubchik, T., Ayoubkhani, D., House, T., MacIntyre-Cockett, G., Fryer, H.R., Thomson, L., Nurtay, A., Kemp, S.A., et al. (2024). Prevalence of persistent SARS-CoV-2 in a large community surveillance study. *Nature* 626, 1094–1101. <https://doi.org/10.1038/s41586-024-07029-4>.
13. Tejerina, F., Catalan, P., Rodriguez-Grande, C., Adan, J., Rodriguez-Gonzalez, C., Muñoz, P., Aldamiz, T., Diez, C., Perez, L., Fanciulli, C., et al. (2022). Post-COVID-19 syndrome. SARS-CoV-2 RNA detection in plasma, stool, and urine in

- patients with persistent symptoms after COVID-19. *BMC Infect. Dis.* 22, 211. <https://doi.org/10.1186/s12879-022-07153-4>.
14. Ceulemans, L.J., Khan, M., Yoo, S.-J., Zapiec, B., Van Gerven, L., Van Slambrouck, J., Vanstapel, A., Van Raemdonck, D., Vos, R., Wauters, E., et al. (2021). Persistence of SARS-CoV-2 RNA in lung tissue after mild COVID-19. *Lancet Respir. Med.* 9, e78–e79. [https://doi.org/10.1016/S2213-2600\(21\)00240-X](https://doi.org/10.1016/S2213-2600(21)00240-X).
15. Craddock, V., Mahajan, A., Spikes, L., Krishnamachary, B., Ram, A.K., Kumar, A., Chen, L., Chalise, P., and Dhillon, N.K. (2023). Persistent Circulation of Soluble and Extracellular vesicle-linked Spike Protein in Individuals with Post-Acute Sequelae of COVID-19. *J. Med. Virol.* 95, e28568. <https://doi.org/10.1002/jmv.28568>.
16. Craddock, V., Mahajan, A., Krishnamachary, B., Spikes, L., Chalise, P., and Dhillon, N.K. (2022). Persistent Presence of Spike protein and Viral RNA in the Circulation of Individuals with Post-Acute Sequelae of COVID-19. Preprint at medRxiv, <https://doi.org/10.1101/2022.08.07.22278520>.
17. Swank, Z., Senussi, Y., Manickas-Hill, Z., Yu, X.G., Li, J.Z., Alter, G., and Walt, D.R. (2023). Persistent Circulating Severe Acute Respiratory Syndrome Coronavirus 2 Spike Is Associated With Post-acute Coronavirus Disease 2019 Sequelae. *Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am.* 76, e487–e490. <https://doi.org/10.1093/cid/ciac722>.
18. Su, Y., Yuan, D., Chen, D.G., Ng, R.H., Wang, K., Choi, J., Li, S., Hong, S., Zhang, R., Xie, J., et al. (2022). Multiple early factors anticipate post-acute COVID-19 sequelae. *Cell* 185, 881-895.e20. <https://doi.org/10.1016/j.cell.2022.01.014>.
19. Dobrowolska, K., Zarębska-Michaluk, D., Poniedziałek, B., Jaroszewicz, J., Flisiak, R., and Rzymski, P. (2023). Overview of autoantibodies in COVID-19 convalescents. *J. Med. Virol.* 95, e28864. <https://doi.org/10.1002/jmv.28864>.
20. Seibert, F.S., Stervbo, U., Wiemers, L., Skrzypczyk, S., Hogeweg, M., Bertram, S., Kurek, J., Anft, M., Westhoff, T.H., and Babel, N. (2023). Severity of neurological Long-COVID symptoms correlates with increased level of autoantibodies targeting vasoregulatory and autonomic nervous system receptors. *Autoimmun. Rev.* 22, 103445. <https://doi.org/10.1016/j.autrev.2023.103445>.
21. Zubchenko, S., Kril, I., Nadizhko, O., Matsyura, O., and Chopyak, V. (2022). Herpesvirus infections and post-COVID-19 manifestations: a pilot observational study. *Rheumatol. Int.* 42, 1523–1530. <https://doi.org/10.1007/s00296-022-05146-9>.
22. Elizalde-Díaz, J.P., Miranda-Narváez, C.L., Martínez-Lazcano, J.C., and Martínez-Martínez, E. (2022). The relationship between chronic immune response and neurodegenerative damage in long COVID-19. *Front. Immunol.* 13, 1039427. <https://doi.org/10.3389/fimmu.2022.1039427>.
23. Nlandu, Y., Tannor, E.K., Bafemika, T., and Makulo, J.-R. (2024). Kidney damage associated with COVID-19: from the acute to the chronic phase. *Ren. Fail.* 46, 2316885. <https://doi.org/10.1080/0886022X.2024.2316885>.
24. Rizvi, A.A., Kathuria, A., Mahmeed, W.A., Al-Rasadi, K., Al-Alawi, K., Banach, M., Banerjee, Y., Ceriello, A., Cesur, M., Cosentino, F., et al. (2022). Post-COVID syndrome, inflammation, and diabetes. *J. Diabetes Complications* 36, 108336. <https://doi.org/10.1016/j.jdiacomp.2022.108336>.

25. Pretorius, E., Venter, C., Laubscher, G.J., Kotze, M.J., Oladejo, S.O., Watson, L.R., Rajaratnam, K., Watson, B.W., and Kell, D.B. (2022). Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with Long COVID/Post-Acute Sequelae of COVID-19 (PASC). *Cardiovasc. Diabetol.* 21, 148. <https://doi.org/10.1186/s12933-022-01579-5>.
26. Charfeddine, S., Ibn Hadj Amor, H., Jdidi, J., Torjmen, S., Kraiem, S., Hammami, R., Bahloul, A., Kallel, N., Moussa, N., Touil, I., et al. (2021). Long COVID 19 Syndrome: Is It Related to Microcirculation and Endothelial Dysfunction? Insights From TUN-EndCOV Study. *Front. Cardiovasc. Med.* 8, 745758. <https://doi.org/10.3389/fcvm.2021.745758>.
27. Tölle, M., Freitag, H., Antelmann, M., Hartwig, J., Schuchardt, M., van der Giet, M., Eckardt, K.-U., Grabowski, P., and Scheibenbogen, C. (2020). Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Efficacy of Repeat Immunoabsorption. *J. Clin. Med.* 9, 2443. <https://doi.org/10.3390/jcm9082443>.
28. Scheibenbogen, C., Loebel, M., Freitag, H., Krueger, A., Bauer, S., Antelmann, M., Doehner, W., Scherbakov, N., Heidecke, H., Reinke, P., et al. (2018). Immunoabsorption to remove β_2 adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME. *PLoS ONE* 13, e0193672. <https://doi.org/10.1371/journal.pone.0193672>.
29. Stein, E., Heindrich, C., Wittke, K., Kedor, C., Kim, L., Freitag, H., Krüger, A., Tölle, M., and Scheibenbogen, C. (2023). Observational Study of Repeat Immunoabsorption (RIA) in Post-COVID ME/CFS Patients with Elevated β_2 -Adrenergic Receptor Autoantibodies—An Interim Report. *J. Clin. Med.* 12, 6428. <https://doi.org/10.3390/jcm12196428>.
30. Gao, Z., Feng, Y., Xu, J., and Liang, J. (2022). T-cell exhaustion in immune-mediated inflammatory diseases: New implications for immunotherapy. *Front. Immunol.* 13, 977394. <https://doi.org/10.3389/fimmu.2022.977394>.
31. Luo, Q., Ye, J., Zeng, L., Luo, Z., Deng, Z., Li, X., Guo, Y., Huang, Z., and Li, J. (2017). Elevated expression of PD-1 on T cells correlates with disease activity in rheumatoid arthritis. *Mol. Med. Rep.* <https://doi.org/10.3892/mmr.2017.8204>.
32. Cabral-Marques, O., and Riemekasten, G. (2017). Functional autoantibodies targeting G protein-coupled receptors in rheumatic diseases. *Nat. Rev. Rheumatol.* 13, 648–656. <https://doi.org/10.1038/nrrheum.2017.134>.
33. Karschnia, M., Zweck, E., Scheiber, D., Heidecke, H., Barthuber, C., Kelm, M., Roden, M., Westenfeld, R., Szendroedi, J., and Boege, F. (2022). Associations of GPCR autoantibodies with clinical, histological, metabolic and hemodynamic features in non-ischemic heart failure patients. *Eur. Heart J.* 43, ehac544.757. <https://doi.org/10.1093/eurheartj/ehac544.757>.
34. Wallukat, G., and Schimke, I. (2014). Agonistic autoantibodies directed against G-protein-coupled receptors and their relationship to cardiovascular diseases. *Semin. Immunopathol.* 36, 351–363. <https://doi.org/10.1007/s00281-014-0425-9>.
35. Wallukat, G., Hohberger, B., Wenzel, K., Fürst, J., Schulze-Rothe, S., Wallukat, A., Hönicke, A.-S., and Müller, J. (2021). Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms. *J. Transl. Autoimmun.* 4, 100100. <https://doi.org/10.1016/j.jtauto.2021.100100>.
36. Cabral-Marques, O., Halpert, G., Schimke, L.F., Ostrinski, Y., Vojdani, A., Baiocchi, G.C., Freire, P.P., Filgueiras, I.S., Zyskind, I., Lattin, M.T., et al. (2022). Autoantibodies targeting GPCRs and RAS-related molecules associate with COVID-19 severity. *Nat. Commun.* 13, 1220. <https://doi.org/10.1038/s41467-022-28905-5>.

37. Cabral-Marques, O., Halpert, G., Schimke, L.F., Ostrinski, Y., Zyskind, I., Lattin, M.T., Tran, F., Schreiber, S., Marques, A.H.C., Filgueiras, I.S., et al. (2021). The relationship between autoantibodies targeting GPCRs and the renin-angiotensin system associates with COVID-19 severity. Preprint at medRxiv, <https://doi.org/10.1101/2021.08.24.21262385>.
38. Hall, J., Bourne, K.M., Vernino, S., Hamrefors, V., Kharraziha, I., Nilsson, J., Sheldon, R.S., Fedorowski, A., and Raj, S.R. (2022). Detection of G Protein–Coupled Receptor Autoantibodies in Postural Orthostatic Tachycardia Syndrome Using Standard Methodology. *Circulation* 146, 613–622. <https://doi.org/10.1161/CIRCULATIONAHA.122.059971>.
39. Kwan, A.C., Ebinger, J.E., Wei, J., Le, C.N., Oft, J.R., Zabner, R., Teodorescu, D., Botting, P.G., Navarrette, J., Ouyang, D., et al. (2022). Apparent risks of postural orthostatic tachycardia syndrome diagnoses after COVID-19 vaccination and SARS-Cov-2 Infection. *Nat. Cardiovasc. Res.* 1, 1187–1194. <https://doi.org/10.1038/s44161-022-00177-8>.
40. Mallick, D., Goyal, L., Chourasia, P., Zapata, M.R., Yashi, K., and Surani, S. (2023). COVID-19 Induced Postural Orthostatic Tachycardia Syndrome (POTS): A Review. *Cureus* 15, e36955. <https://doi.org/10.7759/cureus.36955>.
41. Kedor, C., Freitag, H., Meyer-Arndt, L., Wittke, K., Hanitsch, L.G., Zoller, T., Steinbeis, F., Haffke, M., Rudolf, G., Heidecker, B., et al. (2022). A prospective observational study of post-COVID-19 chronic fatigue syndrome following the first pandemic wave in Germany and biomarkers associated with symptom severity. *Nat. Commun.* 13, 5104. <https://doi.org/10.1038/s41467-022-32507-6>.
42. Ruhe, J., Giszas, B., Schlosser, M., Reuken, P.A., Wolf, G., and Stallmach, A. (2023). Immune adsorption for the treatment of fatigue-dominant long-/post-COVID syndrome. *Dtsch. Ärztebl. Int.* <https://doi.org/10.3238/arztebl.m2023.0073>.
43. Hohberger, B., Harrer, T., Mardin, C., Kruse, F., Hoffmanns, J., Rogge, L., Heltmann, F., Moritz, M., Szewczykowski, C., Schottenhamml, J., et al. (2021). Case Report: Neutralization of Autoantibodies Targeting G-Protein-Coupled Receptors Improves Capillary Impairment and Fatigue Symptoms After COVID-19 Infection. *Front. Med.* 8, 754667. <https://doi.org/10.3389/fmed.2021.754667>.
44. Wu, X., Chen, J., Wu, M., and Zhao, J.X. (2015). Aptamers: Active Targeting Ligands for Cancer Diagnosis and Therapy. *Theranostics* 5, 322–344. <https://doi.org/10.7150/thno.10257>.
45. Daha, N.A., Banda, N.K., Roos, A., Beurskens, F.J., Bakker, J.M., Daha, M.R., and Trouw, L.A. (2011). Complement activation by (auto-) antibodies. *Mol. Immunol.* 48, 1656–1665. <https://doi.org/10.1016/j.molimm.2011.04.024>.
46. Mathsson, L., Ahlin, E., Sjöwall, C., Skogh, T., and Rönnelid, J. (2007). Cytokine induction by circulating immune complexes and signs of in-vivo complement activation in systemic lupus erythematosus are associated with the occurrence of anti-Sjögren's syndrome A antibodies. *Clin. Exp. Immunol.* 147, 513–520. <https://doi.org/10.1111/j.1365-2249.2006.03313.x>.
47. Nielsen, C.H., and Bendtzen, K. (2012). Immunoregulation by naturally occurring and disease-associated autoantibodies: binding to cytokines and their role in regulation of T-cell responses. *Adv. Exp. Med. Biol.* 750, 116–132. https://doi.org/10.1007/978-1-4614-3461-0_9.
48. Ku, C.-L., Chi, C.-Y., Bernuth, H. von, and Doffinger, R. (2020). Autoantibodies against cytokines: phenocopies of primary immunodeficiencies? *Hum. Genet.* 139, 783. <https://doi.org/10.1007/s00439-020-02180-0>.

49. Cheng, A., and Holland, S.M. (2024). Anti-cytokine autoantibodies: mechanistic insights and disease associations. *Nat. Rev. Immunol.* 24, 161–177. <https://doi.org/10.1038/s41577-023-00933-2>.
50. Karin, N. (2018). Autoantibodies to Chemokines and Cytokines Participate in the Regulation of Cancer and Autoimmunity. *Front. Immunol.* 9, 623. <https://doi.org/10.3389/fimmu.2018.00623>.
51. Barzilai, O., Ram, M., and Shoenfeld, Y. (2007). Viral infection can induce the production of autoantibodies. *Curr. Opin. Rheumatol.* 19, 636–643. <https://doi.org/10.1097/BOR.0b013e3282f0ad25>.
52. Ludewig, B., Krebs, P., Metters, H., Tatzel, J., Türeci, Ö., and Sahin, U. (2004). Molecular Characterization of Virus-induced Autoantibody Responses. *J. Exp. Med.* 200, 637–646. <https://doi.org/10.1084/jem.20040358>.
53. Riddell, M.A., Moss, W.J., Hauer, D., Monze, M., and Griffin, D.E. (2007). Slow clearance of measles virus RNA after acute infection. *J. Clin. Virol. Off. Publ. Pan Am. Soc. Clin. Virol.* 39, 312–317. <https://doi.org/10.1016/j.jcv.2007.05.006>.
54. Varkey, J.B., Shantha, J.G., Crozier, I., Kraft, C.S., Lyon, G.M., Mehta, A.K., Kumar, G., Smith, J.R., Kainulainen, M.H., Whitmer, S., et al. (2015). Persistence of Ebola Virus in Ocular Fluid during Convalescence. *N. Engl. J. Med.* 372, 2423–2427. <https://doi.org/10.1056/NEJMoa1500306>.
55. Grobbelaar, L.M., Venter, C., Vlok, M., Ngoepe, M., Laubscher, G.J., Lourens, P.J., Steenkamp, J., Kell, D.B., and Pretorius, E. (2021). SARS-CoV-2 spike protein S1 induces fibrin(ogen) resistant to fibrinolysis: implications for microclot formation in COVID-19. *Biosci. Rep.* 41, BSR20210611. <https://doi.org/10.1042/BSR20210611>.
56. Fontes-Dantas, F.L., Fernandes, G.G., Gutman, E.G., De Lima, E.V., Antonio, L.S., Hammerle, M.B., Mota-Araujo, H.P., Colodeti, L.C., Araújo, S.M.B., Froz, G.M., et al. (2023). SARS-CoV-2 Spike protein induces TLR4-mediated long-term cognitive dysfunction recapitulating post-COVID-19 syndrome in mice. *Cell Rep.* 42, 112189. <https://doi.org/10.1016/j.celrep.2023.112189>.
57. Xiang, Y., Zhang, M., Jiang, D., Su, Q., and Shi, J. (2023). The role of inflammation in autoimmune disease: a therapeutic target. *Front. Immunol.* 14. <https://doi.org/10.3389/fimmu.2023.1267091>.
58. C, S., F, K., L, P. da S., C, N., M, S., Le, B., K, K., J, B., C, S., A, L., et al. (2019). Effectiveness of different immunoadsorption columns for anti-A/B antibody depletion. *Atheroscler. Suppl.* 40. <https://doi.org/10.1016/j.atherosclerosis.2019.08.030>.
59. Woodland, D.L., and Kohlmeier, J.E. (2009). Migration, maintenance and recall of memory T cells in peripheral tissues. *Nat. Rev. Immunol.* 9, 153–161. <https://doi.org/10.1038/nri2496>.
60. Kahan, S.M., Wherry, E.J., and Zajac, A.J. (2015). T Cell Exhaustion During Persistent Viral Infections. *Virology* 0, 180–193. <https://doi.org/10.1016/j.virol.2014.12.033>.
61. Saeidi, A., Zandi, K., Cheok, Y.Y., Saeidi, H., Wong, W.F., Lee, C.Y.Q., Cheong, H.C., Yong, Y.K., Larsson, M., and Shankar, E.M. (2018). T-Cell Exhaustion in Chronic Infections: Reversing the State of Exhaustion and Reinvigorating Optimal Protective Immune Responses. *Front. Immunol.* 9, 2569. <https://doi.org/10.3389/fimmu.2018.02569>.
62. Klein, J., Wood, J., Jaycox, J.R., Dhodapkar, R.M., Lu, P., Gehlhausen, J.R., Tabachnikova, A., Greene, K., Tabacof, L., Malik, A.A., et al. (2023). Distinguishing features of long COVID identified through immune profiling. *Nature* 623, 139–148. <https://doi.org/10.1038/s41586-023-06651-y>.

- 773 63. Yin, K., Peluso, M.J., Luo, X., Thomas, R., Shin, M.-G., Neidleman, J., Andrew,
774 A., Young, K., Ma, T., Hoh, R., et al. (2023). Long COVID manifests with T cell
775 dysregulation, inflammation, and an uncoordinated adaptive immune response to
776 SARS-CoV-2. *BioRxiv Prepr. Serv. Biol.*, 2023.02.09.527892.
777 <https://doi.org/10.1101/2023.02.09.527892>.
- 778 64. Goldberg, T.E., Harvey, P.D., Wesnes, K.A., Snyder, P.J., and Schneider, L.S.
779 (2015). Practice effects due to serial cognitive assessment: Implications for
780 preclinical Alzheimer's disease randomized controlled trials. *Alzheimers Dement.*
781 *Diagn. Assess. Dis. Monit.* 1, 103–111.
782 <https://doi.org/10.1016/j.dadm.2014.11.003>.
- 783 65. Nienen, M., Stervbo, U., Mölder, F., Kaliszczyk, S., Kuchenbecker, L., Gayova, L.,
784 Schweiger, B., Jürchott, K., Hecht, J., Neumann, A.U., et al. (2019). The Role of
785 pre-existing cross-reactive central memory CD4 T-cells in vaccination with
786 previously unseen influenza strains. *Front. Immunol.* 10, 593.
787 <https://doi.org/10.3389/fimmu.2019.00593>.
- 788 66. Bender, R., and Lange, S. (2001). Adjusting for multiple testing—when and how?
789 *J. Clin. Epidemiol.* 54, 343–349. [https://doi.org/10.1016/S0895-4356\(00\)00314-0](https://doi.org/10.1016/S0895-4356(00)00314-0).
- 790 67. Li, G., Taljaard, M., Van Den Heuvel, E.R., Levine, M.Ah., Cook, D.J., Wells,
791 G.A., Devereaux, P.J., and Thabane, L. (2016). An introduction to multiplicity
792 issues in clinical trials: the what, why, when and how. *Int. J. Epidemiol.*, dyw320.
793 <https://doi.org/10.1093/ije/dyw320>.

794

795 Figures and Tables:

796 Table 1. Cohort statistics

Patients (n)	12
Age (Median [Q1-Q3])	50 [34.5-60]
Sex (Female; n (%))	8 (66.7%)
BMI (Median [Q1-Q3])	25.25 [22.1-26.9]
ME/CSF	12 (100%)
- Trigger SARS-CoV-2 infection	4 (33.3%)
- Other trigger, worsened by SARS-CoV-2 infection	8 (66.6%)
Comorbidities	
Arterial hypertension (n (%))	3 (25.0%)
Hyperlipidemia (n (%))	3 (25.0%)
COPD (n (%))	2 (16.7%)
Nicotine abuse (n (%))	2 (16.7%)
ESRD (n (%))	0 (0%)
Diabetes mellitus (n (%))	0 (0%)

797 BMI = Body mass index; COPD = chronic obstructive pulmonary disease; ESRD =
798 End stage renal disease

799

800 Table 2 Reported symptoms, and self-rated physical and mental health

Test	Parameter	Before IA	Follow-Up month)	(1 P-Value
Self rated physical and mental health				
SF-36 questionnaire				
	SF36-Total Score (Mean (SD))	29,7 (7.2)	31,7 (11.9)	0.57 [¥]
	Physical health			
	Physical functioning (Mean (SD))	29,2 (16.2)	29,1 (18.8)	0.67 [¥]
	Role-physical (Mean (SD))	8,3 (15.6)	2,3 (7.2)	0.37 [¥]
	Mental health			
	Mental health (Mean (SD))	51,7 (14.1)	60,7 (16.7)	0.12 [¥]
	Vitality (Mean (SD))	13,9 (13.19)	15,9 (12)	1.00 [¥]
	Role-emotional (Mean (SD))	66,6 (43.1)	81,8 (38.6)	0.41 [¥]
	Social functioning (Mean (SD))	13,4 (14)	17 (15.3)	0.31 [¥]
	General health (Mean (SD))	22 ± (2)	22,7 (12.3)	0.72 [¥]
	Bodily pain (Mean (SD))	28,6 (27)	36,2 (25.5)	0.09 [¥]
Other questionnaires				
	Chalder Fatigue Scale (bm) (Mean (SD))	10.3 (0.9)	9.2 (2.2)	0.28 [¥]
	Bell Score (Mean (SD))	30 (7.4)	31.8 (11.1)	0.57 [¥]
	Canadian criteria for ME/CFS (n (%))	10/11 (90.9%)	9/11 (81.8%)	1.00*
	neurological/cognitive manifestations (n (%))	11/11 (100%)	10/11 (90.9%)	1.00*
	Immunological manifestations (n (%))	11/11 (100%)	11/11 (100%)	1.00*
Self reported symptoms				
	Flu-like symptoms (n (%))	10/11 (90.9%)	10/11 (90.9%)	1.00*
	Persistent cough (n (%))	1/11 (9.1%)	0/11 (0%)	1.00*
	Dyspnoe (n (%))	10/11 (90.9%)	8/11 (72.7%)	0.57*
	Tiredness (n (%))	11/11 (100%)	11/11 (100%)	1.00*
	Respiratory pain (n (%))	0/11 (0%)	1/11 (9.1%)	1.00*
	Thoracic Pain (n (%))	2/11 (18.2%)	1/11 (9.1%)	1.00*
	Odor changes (n (%))	2/11 (18.2%)	1/11 (9.1%)	1.00*
	Changes in taste (n (%))	2/11 (18.2%)	1/11 (9.1%)	1.00*
	Rhinorrhoe (n (%))	5/11 (45.5%)	6/11 (54.5%)	1.00*
	Cephalgien (n (%))	10/11 (90.9%)	11/11 (100%)	1.00*
	Myalgien (n (%))	8/11 (72.7%)	7/11 (63.6%)	1.00*
	Limb pain (n (%))	8/11 (72.7%)	8/11 (72.7%)	1.00*
	Unusual abdominal pain (n (%))	4/11 (36.4%)	4/11 (36.4%)	1.00*
	Nausea (n (%))	2/11 (18.2%)	0/11 (0%)	0.47*
	Diarrhoea (n (%))	3/11 (27.3%)	1/11 (9.1%)	0.59*
	Confusion, disorientation or drowsiness (n (%))	4/11 (36.4%)	2/11 (18.2%)	0.64*
	Brain Fog (n (%))	10/11 (90.9%)	11/11 (100%)	1.00*
	Sleep disorders (n (%))	9/11 (81.8%)	9/11 (81.8%)	1.00*
	Lack of drive (n (%))	3/11 (27.3%)	2/11 (18.2%)	1.00*

801 SD = standard deviation; bm = bimodular; * = Fisher's Exact Test, ¥ = Mann Whitney

802 U Test





803

Figure 1. Influence of IA-Therapy on ANSR -AABs and physiological, neuropsychological and cardiological health. (A) Study protocol and time points for various examinations and blood samples. (B) ELISA analysis of the concentration of $\beta 1/\beta 2$ -adrenoceptors and muscarinic M3/M4 receptors before IA (D0), immediately after the last IA session (D10), and 30 days later (D40). (C) Hand strength measurement before and 30 days after the last IA session. (D) Results of the neuropsychological test battery CERAD-Plus before and 30 days after the last IA session. Pairwise Man-Whitney U Test was performed.


Figure 2. Temporary reduction of pro-inflammatory cytokines after IA-Therapy. Analysis of the cytokine profile of IA patients before IA, immediately after IA and 30 days after the last IA. Pairwise Man-Whitney U Test was performed.

Figure 3. Percentage of T cell populations and ANSR-specific T cells. PBMCs from patients were isolated before IA (D0), and 30 days after the last IA (D40) and stained with the appropriate antibodies and analyzed in a flow-cytometer. (A+C) T cells were identified as $CD3^+$ and $CD4^+$ or $CD8^+$. Naïve and memory T cells were distinguished by expression of CD45RA and CCR7, follicular helper cells by CXCR5 and exhausted T cells by expression of PD-1. CM = Central Memory, EM = Effector Memory. (B+D) PBMC were stimulate for 18h with SARS-CoV-2 Spike OPPs, $\beta 1/\beta 2$ -adrenoreceptors or muscarinic M3/M4 receptor cell lysates, stained with the appropriate antibodies and analyzed in a flow-cytometer. Activated T helper cells were identified as $CD4^+ CD154^+ CD137^+$ and activated cytotoxic T cells as $CD8^+ CD137^+$. Pairwise Man-Whitney U Test was performed. Gating strategies are depicted in supplementary figure S5+S6.



Figure 4. Some of the patients have soluble spike protein, which is correlated with ANSR AAB and blood levels of cytokines. (A) Concentration of spike protein in all spike positive patients (6/12). (B) Concentration of serum antibodies against SARS-CoV-2 spike protein. (C) Percentage of spike protein specific T cells. PBMC were stimulated for 18h with a SARS-CoV-2 spike protein overlapping peptide pool. Spike specific T helper cells were identified as $CD4^+ CD154^+ CD137^+$ and spike specific cytotoxic T cells as $CD8^+ CD137^+$ among all CD4 or CD8 T cells. (D+E) Correlation matrices of spike+ and spike- patients with ANSR AABs vs. blood cytokines (D) and neurological test (E). All collected values were tested for correlation. *P*-values are shown as asterisks within the boxes. **p* < 0.05, ***p* < 0.01, ****p* < 0.001, *****p* < 0.0001. Color grading refers to Spearman's rho rank correlation and is indicated as legend underneath the correlation matrix.

A**B****C****D**


IL-4




IL-2

IL-1 β 


TNF





IL-17A



IL-12p70




IL-8


TGF β 1

A


CD4+ T cells




Naive CD4+




CM CD4+




EM CD4+




CXCR5+ CD4+




PD1 CD4+

**B**


CD4+CD154+CD137+

**C**


CD8+ T cells




Naive CD8+




CM CD8+




EM CD8+



TEMRA CD8+



PD1 CD8+

**D**

CD8+CD137+

